Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

CRISPR Collaboration Announced Between Regeneron and Intellia Therapeutics

XTALKS VITALS NEWS

CRISPR

In addition to developing and marketing new therapies, the two companies plan to further advance the CRISPR/Cas9 gene editing tool.

Share this!

April 14, 2016 | by Sarah Massey, M.Sc.

Biotech company Regeneron Pharmaceuticals and gene editing company Intellia Therapeutics, have announced a licensing and collaboration agreement using the CRISPR/Cas9 technique to develop new therapies for a range of diseases. In addition to developing and marketing new therapies, the two companies plan to further advance the CRISPR/Cas9 gene editing tool.

Intellia is set to receive a $75 million upfront payment from Regeneron, with further payments to be dependent upon milestone achievement and successful commercialization of any gene editing-based therapies. The six-year agreement will permit Regeneron to develop CRISPR-based therapies for a maximum of 10 disease targets, the majority of which could be treated by applying the gene editing technique to liver cells.

The first target for the partnership will be transthyretin amyloidosis, a progressive disease in which deposits of amyloid protein accumulate in organs and tissues throughout the body. These deposits most often buildup in the peripheral nervous system, however they can also affect the functioning of vital organs, including the heart, kidneys and gastrointestinal tract.



“Our industry-leading human genetics research with the Regeneron Genetics Center is already identifying important genetic targets, building on our long- standing expertise in genetic engineering,” said Dr. George D. Yancopoulos, Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. “We believe combining these capabilities with Intellia's technology holds real promise for serious diseases that have been historically difficult to address, and expands our ability to help patients where antibody-based therapies may not be the optimal solution.”

The CRISPR/Cas9 gene editing tool allows researchers to precisely repair specific sequences of DNA, representing a potentially breakthrough therapy for a number of genetic diseases. The technology could be applied to developing new treatments for autoimmune diseases, cancers, and rare inheritable conditions.

“We are excited to be partnering with Regeneron, an industry leader in human genetics research,” said Dr. Nessan Bermingham, Chief Executive Officer and Founder, Intellia Therapeutics. “Regeneron's focus on advancing science to medicine is an excellent fit with Intellia's approach, and together, we aim to bring potential cures to patients who are suffering from life-threatening rare diseases and genetic diseases.”


Keywords: CRISPR, Biotech, Gene Editing


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

READ THESE NEXT
Nanoparticles Could Be Used To Treat Inflammatory Bowel Disease

April 12, 2016 - Researchers at the Institute for Biomedical Sciences at Georgia State University in the US, and Southwest University in China, have designed a novel nanoparticle capable of blocking expression of a glycoprotein that promotes intestinal inflammation.


AstraZeneca and Eli Lilly Pursue Late-Stage Clinical Trial For Alzheimer’s Drug

April 11, 2016 - Pharmaceutical powerhouses AstraZeneca and Eli Lilly have announced that they will be pushing their experimental Alzheimer’s candidate into a Phase III clinical trial.


FDA Approves Celltrion’s Remicade Biosimilar

April 11, 2016 - Celltrion’s Inflectra – a biosimilar to Janssen Biotech’s Remicade – is the second biosimilar to be approved by the US Food and Drug Administration (FDA).

 
THE XTALKS VITALS LIFE SCIENCE BLOG

The Surprising Link Between Off-Label Prescribing Practices And Adverse Drug Events

REGISTER FOR THESE WEBINARS

Copyright © 2016-2017 Honeycomb Worldwide Inc.